Healthcare is one of two sectors (along with consumer staples) that historically holds up best during US recessions. The reason is structural: medical demand is non-discretionary. People do not stop taking their diabetes medication because unemployment ticks up.
Inside the sector, however, the defensive profile varies wildly. Insurers, hospital operators, drug distributors, and big pharma all have different exposures to government policy, commercial pricing, and patent cycles.
Building a 3-stock recession-proof healthcare basket means picking names with the cleanest combination of recurring revenue, pricing power, and pipeline visibility. UNH, LLY, and ISRG each play a different role in the sector, each has a moat that does not depend on the next FDA decision or election, and each has produced strong long-term returns through the past three US economic cycles.
Why Healthcare Holds Up in Recessions
During the 2008 recession, the S&P 500 fell roughly 38 percent peak to trough. The healthcare sector index fell about 23 percent. During COVID in March 2020, the S&P fell 34 percent and healthcare fell 27 percent.
Healthcare does not avoid drawdowns, but it tends to recover faster because earnings are stickier. Drug consumption is non-cyclical. Surgical procedures get postponed but rarely cancelled. Insurance premiums get paid even when discretionary spending dries up.
Total US health expenditure is now over 4.8 trillion dollars annually per CMS data, and the spending trajectory has compounded through every postwar recession. The full sector breakdown is laid out in our defensive stocks explainer, and the sector ETF context is in our healthcare ETF guide.
UnitedHealth (UNH): Insurance Plus Optum Cash Flow
UnitedHealth Group (UNH) is the largest US health insurer by membership, but the more interesting half of the company is Optum, the in-house pharmacy benefits manager and care services arm. Optum now generates more operating profit than the insurance business and grows faster.
The combined entity collects premiums on roughly 50 million covered lives, and the cash flow profile is unusually defensive: premiums are paid monthly regardless of unemployment, and Medicare Advantage exposure has grown to over 7 million members.
- The bear case is regulatory: Medicare Advantage rate-setting and PBM scrutiny are political year after year.
- The bull case is that the dual insurance plus Optum model is genuinely hard to replicate, and the operating margin compounds because Optum keeps absorbing more of the value chain inside one corporate roof.
UNH has compounded earnings at over 12 percent annually for the past 15 years.
Eli Lilly (LLY): GLP-1 Pipeline as Growth Engine
Eli Lilly (LLY) is the rare healthcare name that combines defensive characteristics with growth-stock-like upside. Mounjaro and Zepbound, both based on the GLP-1 mechanism, have moved obesity from a chronic underserved condition into one of the largest pharmaceutical opportunities in history. Lilly’s manufacturing capacity is the gating constraint, and the company has committed roughly 23 billion dollars in capex to expand fill-finish capacity through 2027.
- The bear case is that Novo Nordisk’s competing GLP-1 franchise (Wegovy, Ozempic) is well-entrenched and that oral GLP-1 alternatives could compress pricing within 5 years.
- The bull case is that even shared dominance of a 100-billion-dollar end market generates years of double-digit revenue growth, and Lilly’s pipeline beyond GLP-1 (Donanemab in Alzheimer’s, Verzenio in oncology) provides the next leg of growth.
Intuitive Surgical (ISRG): Razor-and-Blade Robotic Surgery
Intuitive Surgical (ISRG) makes the da Vinci surgical robot. The installed base is over 8,000 systems globally, and recurring revenue from instruments and accessories has grown to roughly 70 percent of total revenue.
The model is razor-and-blade: hospitals buy the system once, then pay for sterile single-use instruments every procedure. Procedure volumes grow at low double-digits annually, even through recessions, because elective surgeries get delayed but not eliminated.
- The bear case is competition from Medtronic Hugo and Johnson & Johnson Ottava.
- The bull case is the 20-year head start ISRG has on data, training, and clinical evidence, which is the kind of moat that compounds rather than erodes.
Building a Diversified Healthcare Basket
An equal-weighted basket of UNH, LLY, and ISRG creates exposure to managed care, pharma, and medical devices in roughly equal proportions.
Beta is below 1, dividend yield is modest (0.5 to 1.5 percent because most cash gets reinvested), and total return depends on earnings growth, not multiple expansion.
Scale this basket at 5 to 10 percent of a US equity portfolio, paired with a sector ETF if you want broader exposure into biotech and tools.
Conclusion
Healthcare is the defensive sector that does not feel defensive when you read the names. UnitedHealth is regulated insurance plus a fast-growing health services business. Eli Lilly is a defensive pharma with growth-stock upside from GLP-1.
Intuitive Surgical is a recurring-revenue medical device platform with a 20-year data moat. Together they cover the three core profit pools of US healthcare and offer a real recession buffer.
To set up the basket, allocate roughly equal positions across the three names in your Gotrade portfolio and check back semi-annually.
FAQ
Why not just buy a healthcare ETF instead?
ETFs like XLV give broad exposure but include slow-growth names that dilute the thesis. The 3-stock basket targets the highest-conviction sub-sectors with cleaner moats.
What is the biggest risk in this basket?
For UNH, regulatory pressure on Medicare Advantage rate-setting. For LLY, GLP-1 competition. For ISRG, robotic surgery competitive entry from Medtronic and Johnson & Johnson.
Are these dividend payers?
UNH and LLY pay modest dividends. ISRG does not pay one. The thesis here is total return, not income.
How does this basket perform in a strong bull market?
Healthcare typically lags in risk-on rallies, with returns driven more by individual catalyst news than the macro tape.
Leave a comment